Deal Intelligence insights.
Trackers and analysis of major licensing and M&A transactions
Biotech & Pharma Conferences 2027: The Dealmaker’s Calendar
The partnering meetings, scientific congresses and regional forums that shape the 2027 biotech deal year, with confirmed dates and cities for JPM, BIO-Europe, ChinaBio, AACR, ASCO, BIO and more, the 2027 clashes, and which meetings fit which goal.
Best Biotech Deal Advisors & Investment Banks 2026: An Objective Comparison
The leading biotech and pharma deal advisors and investment banks in 2026, compared by deal focus, geography, and engagement model — from bulge-bracket banks to specialist life-science banks to cross-border BD & licensing leaders.
AI Drug Discovery Deal Tracker 2026: Partnerships & M&A
A running tracker of the major AI drug discovery deals — Isomorphic–Lilly/Novartis/J&J, Lilly–NVIDIA, Recursion–Roche, Noetik–GSK — with upfronts, biobucks, and a dealmaker’s analysis of the structures.
China Out-Licensing Report 2026
The signature annual analysis of China→West pharma out-licensing: a record ~$136B across ~157 deals in 2025 (now ~a third of global deal value), the biggest transactions, the ADC and PD-1/VEGF bispecific breakdown, deal-structure trends, and the BIOSECURE context.
The China Discount: Arbitraging Undervalued Chinese ADC & Bispecific Assets
Clinical-stage Chinese assets have traded at upfronts ~60-70% below Western comparables — a discount rooted in domestic price compression, a capital drought and a geopolitical premium. Why the discount exists, how Western pharma arbitrages it (buy global rights cheap, commercialize in the richer West), and whether it is closing in 2026.
Life Sciences M&A in 2026: Deals, Drivers and Synergy Targets
What is happening in life sciences M&A, what is driving it, the largest biopharma, tools, diagnostics and CDMO deals of 2026, and the synergies buyers are promising.
Biotech Licensing Deal Tracker 2026: Top Deals, Trends & Strategic Analysis
A record $274B in 2025 and $221B through Q3 2026. Our verified 2026 licensing deal log with upfronts, totals and sources, plus China’s growing share.
China Biotech Outbound Licensing Tracker 2026: $135.7B in Deal Value
China out-licensing hit $139.4B by early October 2026, already above 2025. Our verified log of the year’s largest China-to-global deals, with stage and terms.
Pharma M&A Tracker 2026: Every Major Acquisition & What's Driving the Surge
$138.9B in biopharma M&A through Q3 2026, already above all of 2025. Our verified log of 2026’s $1B+ acquisitions, with prices, premiums and CVRs.
Pharma Deals Database 2026: Major Licensing and M&A Deals, Verified
A searchable, downloadable database of 2026’s major pharma licensing deals and acquisitions, each verified against its source, with terms, areas and monthly totals.
The Vision Lifesciences brief.
One email per month. New essays and deal-flow notes from the partner team. Unsubscribe anytime.